文献速递新发突发、热带与寄生虫病

妊娠期无并发症与重症疟疾的治疗

Treatment of uncomplicated and severe malaria during pregnancy.
PubMed 文献 · Lancet Infect Dis · 2018-01-31

过去10年妊娠期疟疾治疗证据显著增加。基于富组氨酸蛋白2的快速诊断试验适用于有症状孕妇,但不适合系统筛查。WHO正审查早孕期治疗指南;中晚孕期青蒿素联合疗法安全有效。亟需将证据转化为政策与实践,并加强药物警戒。

要点

  • 基于富组氨酸蛋白2的快速诊断试验适用于有症状孕妇,但因不能检出重要比例的无症状感染,不适合系统筛查。
  • 中晚孕期青蒿素联合疗法安全有效,但耐受性和疗效可能因治疗方案而异。
  • 许多国家和地区寄生虫学诊断或适当抗疟治疗的可及性仍然很低。

核心结论

  • 中晚孕期青蒿素联合疗法安全有效,但耐受性和疗效可能因治疗方案而异。
  • 亟需将证据转化为政策与临床实践,以惠及疟疾流行区的孕妇。
  • 需要研究识别针对孕妇和卫生服务提供者的质量改进干预措施。
  • 需要高效实用的药物警戒系统,以进一步扩展抗疟药安全性知识,尤其是早孕期。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 妊娠期抗疟药 pharmacokinetics 的影响在研究间和药物类别间差异很大,强调需要在孕妇和非孕妇中开展前瞻性研究。
  • 基于富组氨酸蛋白2的快速诊断试验适用于有症状孕妇,但因不能检出重要比例的无症状感染,不适合系统筛查。
  • 多个试验结果证实中晚孕期青蒿素联合疗法安全有效,但耐受性和疗效可能因治疗方案而异。
  • 许多国家和地区寄生虫学诊断或适当抗疟治疗的可及性仍然很低。

关键数值与推荐

  • WHO正在审查早孕期疟疾治疗的国际指南。
  • 中晚孕期青蒿素联合疗法安全有效,但耐受性和疗效可能因治疗方案而异。

临床怎么用

  • 基于富组氨酸蛋白2的快速诊断试验适用于有症状孕妇,但不适合系统筛查。
  • 中晚孕期可使用青蒿素联合疗法,但耐受性和疗效可能因治疗方案而异。
  • 早孕期疟疾治疗的国际指南正在由WHO审查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past 10 years, the available evidence on the treatment of malaria during pregnancy has increased substantially. Owing to their relative ease of use, good sensitivity and specificity, histidine rich protein 2 based rapid diagnostic tests are appropriate for symptomatic pregnant women; however, such tests are less appropriate for systematic screening because they will not detect an important proportion of infections among asymptomatic women. The effect of pregnancy on the pharmacokinetics of antimalarial drugs varies greatly between studies and class of antimalarial drugs, emphasising the need for prospective studies in pregnant and non-pregnant women. For the treatment of malaria during the first trimester, international guidelines are being reviewed by WHO. For the second and third trimester of pregnancy, results from several trials have confirmed that artemisinin-based combination treatments are safe and efficacious, although tolerability and efficacy might vary by treatment. It is now essential to translate such evidence into policies and clinical practice that benefit pregnant women in countries where malaria is endemic. Access to parasitological diagnosis or appropriate antimalarial treatment remains low in many countries and regions. Therefore, there is a pressing need for research to identify quality improvement interventions targeting pregnant women and health providers. In addition, efficient and practical systems for pharmacovigilance are needed to further expand knowledge on the safety of antimalarial drugs, particularly in the first trimester of pregnancy.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. D'Alessandro U, Hill J, Tarning J, et al. Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018. PMID: 29395998. doi:10.1016/S1473-3099(18)30065-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。